Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3025876 in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 26 Jan 2019
At a glance
- Drugs LY 3025876 (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 12 May 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.